Nathan L Liang1, Theodore H Yuo2, Georges E Al-Khoury2, Eric S Hager2, Michel S Makaroun2, Michael J Singh2. 1. Division of Vascular Surgery, Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pa. Electronic address: liangnl@upmc.edu. 2. Division of Vascular Surgery, Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pa.
Abstract
BACKGROUND: Morbidity and mortality have improved with the evolution of endovascular techniques (thoracic endovascular aortic repair [TEVAR]) for thoracic aortic disease, but results after aortic intervention in patients with end-stage renal disease (ESRD) remain unclear. The objective of this study was to evaluate outcomes of open and endovascular descending thoracic aortic repair in dialysis-dependent patients. METHODS: We identified 352 patients with ESRD on dialysis undergoing open repair (n = 136) or TEVAR (n = 216) of the thoracic aorta from 2005 to 2008 using the United States Renal Data System database. Acute presentation was defined as ruptured aneurysm, dissection, or traumatic injury; all other interventions were considered elective. End points were 30-day mortality, overall survival, rates of perioperative complications, and procedural trends over time. Between-group comparisons and survival analysis used standard statistical methods. Logistic regression and Cox regression were performed using multivariate analysis. RESULTS: TEVAR subjects were older than those undergoing open repair (68.2 ± 11.5 vs 60.8 ± 13.2 years; P < .001); no other demographics differed. There were 303 patients who had thoracic or thoracoabdominal aneurysms; 47 (13.4%) were ruptured on presentation. There were 44 patients (12.5%) who had aortic dissection and 5 (1.4%) with aortic trauma. Overall 30-day mortality was 21.3% (n = 75), and it was greater for open repair (n = 41 [30.1%]) than for TEVAR (n = 34 [15.7%]; P = .002). Elective 30-day mortality for open repair (n = 27 [29.3%]) was also greater than for TEVAR (n = 24 [14.3%]; P = .005). Those with acute presentation trended toward higher mortality for open repair (n = 14 [31.8%] vs n = 10 [15.7%]; P = .17). Respiratory failure was higher for open repair (n = 69 [50.7%] vs n = 56 [25.9%]; P < .001); postoperative stroke was higher with TEVAR (n = 21 [9.7%] vs n < 10 [<7%]; P = .02). Estimated 1-year survival was 50% and did not differ between groups (44% for open repair, 53% for TEVAR). In multivariate analysis, TEVAR decreased odds of 30-day mortality compared with open repair (odds ratio, 0.41; 95% confidence interval, 0.24-0.71) but failed to demonstrate long-term survival advantage. CONCLUSIONS: In ESRD patients, TEVAR provides short-term mortality benefits compared with open repair, but long-term mortality remains high regardless of treatment modality. Elective intervention for thoracic aortic disease in this population remains high risk and should be approached with caution.
BACKGROUND: Morbidity and mortality have improved with the evolution of endovascular techniques (thoracic endovascular aortic repair [TEVAR]) for thoracic aortic disease, but results after aortic intervention in patients with end-stage renal disease (ESRD) remain unclear. The objective of this study was to evaluate outcomes of open and endovascular descending thoracic aortic repair in dialysis-dependent patients. METHODS: We identified 352 patients with ESRD on dialysis undergoing open repair (n = 136) or TEVAR (n = 216) of the thoracic aorta from 2005 to 2008 using the United States Renal Data System database. Acute presentation was defined as ruptured aneurysm, dissection, or traumatic injury; all other interventions were considered elective. End points were 30-day mortality, overall survival, rates of perioperative complications, and procedural trends over time. Between-group comparisons and survival analysis used standard statistical methods. Logistic regression and Cox regression were performed using multivariate analysis. RESULTS:TEVAR subjects were older than those undergoing open repair (68.2 ± 11.5 vs 60.8 ± 13.2 years; P < .001); no other demographics differed. There were 303 patients who had thoracic or thoracoabdominal aneurysms; 47 (13.4%) were ruptured on presentation. There were 44 patients (12.5%) who had aortic dissection and 5 (1.4%) with aortic trauma. Overall 30-day mortality was 21.3% (n = 75), and it was greater for open repair (n = 41 [30.1%]) than for TEVAR (n = 34 [15.7%]; P = .002). Elective 30-day mortality for open repair (n = 27 [29.3%]) was also greater than for TEVAR (n = 24 [14.3%]; P = .005). Those with acute presentation trended toward higher mortality for open repair (n = 14 [31.8%] vs n = 10 [15.7%]; P = .17). Respiratory failure was higher for open repair (n = 69 [50.7%] vs n = 56 [25.9%]; P < .001); postoperative stroke was higher with TEVAR (n = 21 [9.7%] vs n < 10 [<7%]; P = .02). Estimated 1-year survival was 50% and did not differ between groups (44% for open repair, 53% for TEVAR). In multivariate analysis, TEVAR decreased odds of 30-day mortality compared with open repair (odds ratio, 0.41; 95% confidence interval, 0.24-0.71) but failed to demonstrate long-term survival advantage. CONCLUSIONS: In ESRDpatients, TEVAR provides short-term mortality benefits compared with open repair, but long-term mortality remains high regardless of treatment modality. Elective intervention for thoracic aortic disease in this population remains high risk and should be approached with caution.
Authors: Philip P Goodney; Lori Travis; F Lee Lucas; Mark F Fillinger; David C Goodman; Jack L Cronenwett; David H Stone Journal: Circulation Date: 2011-11-21 Impact factor: 29.690
Authors: Salvatore T Scali; Philip P Goodney; Daniel B Walsh; Lori L Travis; Brian W Nolan; David C Goodman; F Lee Lucas; David H Stone Journal: J Vasc Surg Date: 2011-06 Impact factor: 4.268
Authors: Raja R Gopaldas; Joseph Huh; Tam K Dao; Scott A LeMaire; Danny Chu; Faisal G Bakaeen; Joseph S Coselli Journal: J Thorac Cardiovasc Surg Date: 2010-11 Impact factor: 5.209
Authors: Ryan R Davies; Lee J Goldstein; Michael A Coady; Shawn L Tittle; John A Rizzo; Gary S Kopf; John A Elefteriades Journal: Ann Thorac Surg Date: 2002-01 Impact factor: 4.330
Authors: Michel S Makaroun; Ellen D Dillavou; Stephen T Kee; Gregorio Sicard; Elliot Chaikof; Joseph Bavaria; David Williams; Richard P Cambria; R Scott Mitchell Journal: J Vasc Surg Date: 2005-01 Impact factor: 4.268
Authors: Lars G Svensson; Nicholas T Kouchoukos; D Craig Miller; Joseph E Bavaria; Joseph S Coselli; Michael A Curi; Holger Eggebrecht; John A Elefteriades; Raimund Erbel; Thomas G Gleason; Bruce W Lytle; R Scott Mitchell; Christoph A Nienaber; Eric E Roselli; Hazim J Safi; Richard J Shemin; Gregorio A Sicard; Thoralf M Sundt; Wilson Y Szeto; Grayson H Wheatley Journal: Ann Thorac Surg Date: 2008-01 Impact factor: 4.330
Authors: Benjamin R Griffin; Patrick D Kohtz; Michael Bronsert; T Brett Reece; Joseph C Cleveland; David A Fullerton; Sarah Faubel; Muhammad Aftab Journal: J Surg Res Date: 2019-11-27 Impact factor: 2.192